Alzheimer's disease is challenging.
Treatment doesn’t have to be.

Built on established galantamine efficacy, ZUNVEYL is purposefully designed to support meaningful outcomes across cognition, behavior, and activities of daily living (ADLs).

ZUNVEYL impacts the hallmark symptoms of Alzheimer’s disease: cognition, behavior, and activities of daily living (ADLs)

One purposefully designed therapy. Three meaningful outcomes.

Cognition

Demonstrated Cognitive Benefit

ZUNVEYL has shown sustained benefit on cognitive outcomes, including memory, attention, orientation, language, and reasoning.

View Cognition Results

Behavior

Impact Across Behavioral Symptoms

ZUNVEYL demonstrated benefit on behavioral symptoms in clinical studies, including improvements measured by the Neuropsychiatric Inventory (NPI).

See Behavioral Outcomes

Activities of Daily Living

Support for Everyday Function

Clinical studies demonstrated benefit in activities of daily living, helping assess how patients function in day-to-day life.

Explore Clinical Data

Purposefully Designed for the Realities of Treating Alzheimer's Disease

  • First and only FDA-approved acetylcholinesterase inhibitor utilizing prodrug enteric-coated, delayed-release technology1,2
  • Enhances acetylcholine levels while minimizing absorption in the stomach1
  • Designed to reduce overstimulation of neurons in the gastrointestinal nervous system1-3
How ZUNVEYL Works

Explore More About ZUNVEYL

Dosing & Administration

Learn about ZUNVEYL's recommended dosing schedule, titration guidance, and administration considerations for your residents.

View Dosing Information

Real World Evidence

Explore real-world and post-hoc data examining the impact of galantamine on sleep outcomes and long-term disease progression.

See Real-World Data

Access Support & Tools

Submit a Service Request Form for prior authorization or appeal assistance, download reimbursement tools, and access CoverMyMeds® to help your residents start and stay on ZUNVEYL.

Explore Access Resources

Connect with a ZUNVEYL Representative

Connect with an Alpha Cognition representative to discuss how ZUNVEYL may be appropriate for your residents.

Request a Rep

Need Help with Prior Authorization?

Submit a Service Request Form and Alpha Cognition will help support your residents' access to ZUNVEYL.

Start Service Request Form

INDICATION AND USAGE

ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

ZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredients in ZUNVEYL. Serious skin reactions have occurred.

WARNINGS AND PRECAUTIONS

Serious Skin Reactions: Serious skin reactions (Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) have been reported in patients receiving galantamine (the active metabolite of ZUNVEYL tablets). If signs or symptoms suggest a serious skin reaction, use of this drug should not be resumed, and alternative therapy should be considered.

Anesthesia: See Drug Interactions Section

Cardiovascular Conditions: Cholinesterase inhibitors, including ZUNVEYL, have vagotonic effects on the sinoatrial and atrioventricular nodes, leading to bradycardia and AV block. Bradycardia and all types of heart block have been reported in patients taking cholinesterase inhibitors, both with and without known underlying cardiac conduction abnormalities. Therefore, all patients should be considered at risk for adverse effects on cardiac conduction.

Patients treated with galantamine up to 24 mg/day using the recommended dosing schedule showed a dose-related increase in risk of syncope.

Gastrointestinal Conditions: Cholinesterase inhibitors, including ZUNVEYL, may increase gastric acid secretion. Patients should be monitored closely for active or occult gastrointestinal bleeding, especially those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical studies of galantamine have shown no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding.

Galantamine has been shown to produce nausea, vomiting, diarrhea, anorexia, and weight loss. Monitor the patient's weight during therapy with ZUNVEYL.

Genitourinary Conditions: Although this was not observed in clinical trials with galantamine, cholinesterase inhibitors, including ZUNVEYL, may cause bladder outflow obstruction.

Neurological Conditions: Cholinesterase inhibitors are believed to have some potential to cause generalized convulsions. Seizure activity may also be a manifestation of Alzheimer's disease. Patients with Alzheimer's disease should be monitored closely for seizures while taking ZUNVEYL.

Pulmonary Conditions: Cholinesterase inhibitors, including ZUNVEYL, should be prescribed with care to patients with a history of severe asthma or obstructive pulmonary disease. Monitor for respiratory adverse reactions.

ADVERSE REACTIONS

The most common adverse reactions with galantamine tablets (≥5%) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.

DRUG INTERACTIONS

Use with Anticholinergics: Galantamine has the potential to interfere with the activity of anticholinergic medications.

Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect is expected when cholinesterase inhibitors are given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.

USE IN SPECIFIC POPULATIONS

Pregnancy: Based on animal data may cause fetal harm.

Hepatic Impairment: In patients with moderate hepatic impairment, a decrease in clearance of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with severe hepatic impairment is not recommended.

Renal Impairment: In patients with a creatinine clearance of 9 to 59 mL/min, an increase in exposure of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with creatinine clearance less than 9 mL/min is not recommended.

For more information about ZUNVEYL, please see the full Prescribing Information here.